1 2 3 4 "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization. 2020-04-27. สืบค้นเมื่อ 2020-05-02. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale
1 2 3 4 5 "Launch of a European clinical trial against COVID-19". INSERM. 22 March 2020. สืบค้นเมื่อ 5 April 2020. The great strength of this trial is its 'adaptive' nature. This means that ineffective experimental treatments can very quickly be dropped and replaced by other molecules that emerge from research efforts. We will therefore be able to make changes in real time, in line with the most recent scientific data, in order to find the best treatment for our patients
↑ Mullard, Asher (2020-04-18). "Flooded by the torrent: the COVID-19 drug pipeline". The Lancet (in English). 395 (10232): 1245–1246. doi:10.1016/S0140-6736(20)30894-1.CS1 maint: Unrecognized language (link)
